Craig Evelyn L, Zhao Bin, Cui Jason Z, Novalen Maria, Miksys Sharon, Tyndale Rachel F
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Departments of Pharmacology & Toxicology and Psychiatry, University of Toronto, Toronto, Ontario, Canada (E.L.C., B.Z., M.N., S.M., R.F.T.) and Child & Family Research Institute, Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (J.Z.C.).
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Departments of Pharmacology & Toxicology and Psychiatry, University of Toronto, Toronto, Ontario, Canada (E.L.C., B.Z., M.N., S.M., R.F.T.) and Child & Family Research Institute, Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (J.Z.C.)
Drug Metab Dispos. 2014 Sep;42(9):1447-55. doi: 10.1124/dmd.114.058719. Epub 2014 Jun 30.
Several behavioral studies report that adolescent rats display a preference for nicotine compared with adults. However, age-related pharmacokinetic differences may confound the interpretation of these findings. Thus, differences in pharmacokinetic analyses of nicotine were investigated. Nicotine was administered via acute s.c. (1.0 mg base/kg) or i.v. (0.2 mg base/kg) injection to early adolescent (EA; postnatal day 25) and adult (AD; postnatal day 71) male Wistar rats. Nicotine and its primary metabolite, cotinine, and additional metabolites nornicotine, nicotine-1'-N-oxide, trans-3'-hydroxycotinine, and norcotinine were sampled from 10 minutes to 8 hours (plasma) and 2 to 8 hours (brain) post nicotine and analyzed by liquid chromatography-tandem mass spectrometry. Following s.c. nicotine, the EA cohort had lower levels of plasma nicotine, cotinine, and nicotine-1'-N-oxide at multiple time points, resulting in a lower area under the plasma concentration-time curve (AUC) for nicotine (P < 0.001), cotinine (P < 0.01), and nicotine-1'-N-oxide (P < 0.001). Brain levels were also lower for these compounds. In contrast, the EA cohort had higher plasma and brain AUCs (P < 0.001) for the minor metabolite nornicotine. Brain-to-plasma ratios varied for nicotine and its metabolites, and by age. Following i.v. nicotine administration, similar age-related differences were observed, and this route allowed detection of a 1.6-fold-larger volume of distribution and 2-fold higher plasma clearance in the EA cohort compared with the AD cohort. Thus, unlike in humans, there are substantial age differences in nicotine pharmacokinetics such that for a given nicotine dose, adolescent rats will have lower plasma and brain nicotine compared with adults, suggesting that this should be considered when interpreting animal model data.
多项行为学研究报告称,与成年大鼠相比,青春期大鼠对尼古丁表现出偏好。然而,与年龄相关的药代动力学差异可能会混淆这些研究结果的解读。因此,对尼古丁的药代动力学分析差异进行了研究。通过急性皮下注射(1.0 mg碱/kg)或静脉注射(0.2 mg碱/kg)尼古丁,将其给予青春期早期(EA;出生后第25天)和成年(AD;出生后第71天)雄性Wistar大鼠。在注射尼古丁后10分钟至8小时(血浆)和2至8小时(脑)采集尼古丁及其主要代谢物可替宁,以及其他代谢物去甲烟碱、尼古丁-1'-N-氧化物、反式-3'-羟基可替宁和去甲可替宁,并通过液相色谱-串联质谱法进行分析。皮下注射尼古丁后,在多个时间点,EA组的血浆尼古丁、可替宁和尼古丁-1'-N-氧化物水平较低,导致尼古丁(P < 0.001)、可替宁(P < 0.01)和尼古丁-1'-N-氧化物(P < 0.001)的血浆浓度-时间曲线下面积(AUC)较低。这些化合物的脑内水平也较低。相比之下,EA组次要代谢物去甲烟碱的血浆和脑AUC较高(P < 0.001)。尼古丁及其代谢物的脑-血浆比值因物质和年龄而异。静脉注射尼古丁后,观察到类似的与年龄相关的差异,并且与AD组相比,该给药途径使得EA组的分布容积大1.6倍,血浆清除率高2倍。因此,与人类不同,尼古丁药代动力学存在显著的年龄差异,对于给定的尼古丁剂量,青春期大鼠的血浆和脑内尼古丁水平低于成年大鼠,这表明在解释动物模型数据时应考虑这一点。